Equities Analysts Offer Predictions for argenx Q3 Earnings

argenx SE (NASDAQ:ARGX - Free Report) - Equities research analysts at Wedbush lifted their Q3 2025 earnings per share (EPS) estimates for shares of argenx in a report issued on Thursday, May 8th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $5.38 for the quarter, up from their prior forecast of $5.17. Wedbush currently has a "Outperform" rating and a $715.00 target price on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenx's FY2025 earnings at $18.73 EPS and FY2027 earnings at $43.06 EPS.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%.

Several other equities analysts have also issued reports on ARGX. Citigroup reiterated an "outperform" rating on shares of argenx in a report on Wednesday. Truist Financial reissued a "buy" rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Guggenheim cut their target price on argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $698.11.

argenx Stock Down 1.9%

Shares of ARGX stock traded down $10.20 during trading hours on Monday, hitting $532.27. 486,197 shares of the company's stock traded hands, compared to its average volume of 322,097. The stock's fifty day simple moving average is $593.35 and its two-hundred day simple moving average is $613.35. argenx has a 12-month low of $352.77 and a 12-month high of $678.21. The stock has a market cap of $32.50 billion, a price-to-earnings ratio of -604.85 and a beta of 0.57.

Institutional Trading of argenx

Hedge funds have recently bought and sold shares of the company. GeoWealth Management LLC boosted its holdings in shares of argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the last quarter. Rakuten Securities Inc. lifted its position in shares of argenx by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after acquiring an additional 22 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in shares of argenx in the fourth quarter valued at about $37,000. Global Retirement Partners LLC lifted its position in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. Finally, FIL Ltd purchased a new stake in argenx during the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.